Skip to main content

Solventum Corporation (SOLV) Receives a Buy from Stifel Nicolaus

Tipranks - Tipranks - Sat Feb 28, 11:16AM CST

In a report released today, Rick Wise from Stifel Nicolaus maintained a Buy rating on Solventum Corporation, with a price target of $105.00.

Claim 50% Off TipRanks Premium

Wise covers the Healthcare sector, focusing on stocks such as Boston Scientific, Edwards Lifesciences, and GE Healthcare Technologies Inc. According to TipRanks, Wise has an average return of -0.7% and a 49.60% success rate on recommended stocks.

In addition to Stifel Nicolaus, Solventum Corporation also received a Buy from Piper Sandler’s Jason Bednar in a report issued today. However, on the same day, TipRanks – Anthropic reiterated a Hold rating on Solventum Corporation (NYSE: SOLV).

See today’s best-performing stocks on TipRanks >>

Based on Solventum Corporation’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $2 billion and a net profit of $63 million. In comparison, last year the company earned a revenue of $2.08 billion and had a net profit of $31 million

Read More on SOLV:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).